ReviewDiscoveries (Craiova, Romania)
Ischemic Preconditioning in Atrial Fibrillation.
Review in Discoveries (Craiova, Romania). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia worldwide with treatments such as anticoagulants, rate control, and catheter ablation only aiming to reduce complications. Ischemic preconditioning (IPC), defined as brief cycles of ischemia followed by reperfusion, has emerged as a promising cardioprotective strategy. This review aims to provide a comprehensive review on and discuss recent trials surrounding the use of ischemic preconditioning as a promising therapeutic alternative in the treatment of atrial fibrillation. Clinical trials in both surgical and interventional settings have shown encouraging evidence that these protective mechanisms can lead to meaningful reductions in atrial arrhythmia. Despite these encouraging findings, heterogeneity persists likely due to differences in patient selection, anesthetic regimens, and the timing or protocols of preconditioning. The collective evidence highlights the therapeutic potential surrounding the use of ischemic preconditioning in atrial fibrillation. With recent trials on the rise, IPC's potential impact on rhythm control, pharmacologic responsiveness, cardioversion outcomes, and complication rates is highly promising for the treatment of atrial fibrillation. Further research is required to translate these findings into routine clinical practice, particularly in high-risk populations such as those with concurrent heart failure or structural heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.